The National Institute for Health and Welfare (THL) has conducted a study of HPV vaccine administered to girls in the years 2013–2015. The study investigated whether the vaccine increases the risk of autoimmune disorders. There were approximately 241,000 subjects in all. Approximately half of them, or 56 percent, received the vaccine. HPV vaccine prevents HPV viral infection and the precursors of cervical cancer that it causes.
The seasonal influenza vaccine is included in the National Immunisation Programme for young children, pregnant women, members of risk groups and their household contacts and carers, people over 65 years of age, social and health care personnel, and conscripts.
Others can take the vaccine at their own expense or it may be included in one's occupational health care. Influenza viruses change rapidly so the vaccination offers protection only one influenza season at a time.
For the first time, it has been shown that vaccines against human papillomavirus (HPV) prevent malignant HPV-associated cancers in women. This was the finding of a Finnish-Swedish research team coordinated by the University of Tampere. The finding was based on registry monitoring of Finnish subjects in randomised HPV-vaccinated and control cohorts.
The national vaccination register of Finland shows that influenza vaccination coverage of children below three years of age improved by three percentage points this season. Influenza vaccination coverage for people 65 years of age and older also increased slightly and is currently at 48 per cent.